<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetol Metab Syndr</journal-id><journal-id journal-id-type="iso-abbrev">Diabetol Metab Syndr</journal-id><journal-title-group><journal-title>Diabetology &#x00026; Metabolic Syndrome</journal-title></journal-title-group><issn pub-type="epub">1758-5996</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28572856</article-id><article-id pub-id-type="pmc">5452348</article-id><article-id pub-id-type="publisher-id">239</article-id><article-id pub-id-type="doi">10.1186/s13098-017-0239-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Unacylated ghrelin modulates circulating angiogenic cell number in insulin-resistant states</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>&#x000d6;zcan</surname><given-names>Behiye</given-names></name><address><phone>+31 10 703 2862</phone><email>b.ozcan@erasmusmc.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Leenen</surname><given-names>Pieter J. M.</given-names></name><address><email>p.leenen@erasmusmc.nl</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Delhanty</surname><given-names>Patric J. D.</given-names></name><address><email>p.delhanty@erasmusmc.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bald&#x000e9;on-Rojas</surname><given-names>Lucy Y.</given-names></name><address><email>l.baldeonrojas@erasmusmc.nl</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Neggers</surname><given-names>Sebastian J.</given-names></name><address><email>s.neggers@erasmusmc.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>van der Lely</surname><given-names>Aart Jan</given-names></name><address><email>a.vanderlelij@erasmusmc.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">000000040459992X</institution-id><institution-id institution-id-type="GRID">grid.5645.2</institution-id><institution>Department of Internal Medicine, </institution><institution>Erasmus MC, </institution></institution-wrap>Rotterdam, The Netherlands </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">000000040459992X</institution-id><institution-id institution-id-type="GRID">grid.5645.2</institution-id><institution>Department of Immunology, </institution><institution>Erasmus MC, </institution></institution-wrap>Rotterdam, The Netherlands </aff></contrib-group><pub-date pub-type="epub"><day>31</day><month>5</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>31</day><month>5</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>9</volume><elocation-id>43</elocation-id><history><date date-type="received"><day>17</day><month>10</month><year>2016</year></date><date date-type="accepted"><day>17</day><month>5</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Type 2 diabetes (T2D) is associated with reduced numbers and impaired function of circulating angiogenic cells (CAC) which contributes to the progression of atherosclerosis and microvascular disease. Previous studies suggest that short-term infusion of unacylated ghrelin (UAG) normalizes CAC number in patients with T2D. To determine dose-dependent effects of short-term infusion of UAG in T2D patients using a cross-over model, and of long-term infusion of UAG in obese mice, on differentiation of monocyte progenitors into CAC.</p></sec><sec><title>Methods</title><p>Eight overweight T2D patients were infused overnight with 3 and 10&#x000a0;&#x000b5;g/kg/h of UAG in a double-blind, placebo-controlled cross-over study. To assess the effects of long-term UAG treatment, obese mice were infused with UAG for 4&#x000a0;weeks. Monocyte progenitors were assessed for their ability to differentiate into CAC in vitro.</p></sec><sec><title>Results</title><p>In T2D patients, UAG treatment caused a reduction in differentiation of CAC, dependent on UAG dose and differentiation method. However, mice treated with UAG showed a significant increase in differentiation of bone marrow progenitors into CAC.</p></sec><sec><title>Conclusion</title><p>UAG causes a minor suppressive effect on CAC development after short-term treatment in humans, but experiments in mice suggest that long-term treatment has beneficial effects on CAC formation.</p><p>The Netherlands Trial Register: TC=2487</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Diabetes</kwd><kwd>Circulating angiogenic cell</kwd><kwd>Unacylated ghrelin</kwd><kwd>Insulin resistant</kwd><kwd>Obese</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Ghrelin is a 28 amino acid peptide that is secreted predominantly by X/A-like cells in the stomach. It circulates in two different forms: acylated ghrelin (AG) and unacylated ghrelin (UAG; also named des-acyl ghrelin) [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. AG is acylated with octanoic acid at serine 3 by ghrelin <italic>O</italic>-acyl transferase (GOAT), whereas UAG is not [<xref ref-type="bibr" rid="CR3">3</xref>]. Ghrelin was discovered in 1999 as the endogenous ligand of the orphan growth hormone secretagogue receptor (GHSR1a) that had previously been identified as the receptor mediating the pharmacological effects of a new therapeutic class of compounds, the growth hormone secretagogues [<xref ref-type="bibr" rid="CR4">4</xref>]. Ghrelin was initially characterized for its property of inducing growth hormone (GH) secretion, a function mediated by GHSR1a [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p>Today, however the ghrelin system is known to exert numerous biological effects on the secretion of several pituitary hormones, on gastric acid secretion and gut-motility, on exocrine and endocrine pancreatic function and glucose metabolism, appetite stimulation and the cardio-vascular and immune system [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Since UAG only activates GHSR1a at supra-physiological concentrations [<xref ref-type="bibr" rid="CR6">6</xref>], and has no physiological effect on GH secretion [<xref ref-type="bibr" rid="CR7">7</xref>], it has long been considered not to have a physiological role.</p><p>Clinical evidence suggests that UAG prevents the diabetogenic effects of AG in healthy volunteers and in GH-deficient patients [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR8">8</xref>], primarily by improving insulin-sensitivity. Importantly, we have recently shown that UAG treatment rapidly improves insulin sensitivity in type 2 diabetic subjects [<xref ref-type="bibr" rid="CR9">9</xref>]. How it can exert effects in several disparate (patho)physiological systems and conditions remains to be answered. In metabolically active tissues of GHSR-deficient mice, UAG rapidly modulates lipogenic and insulin signaling pathway gene expression [<xref ref-type="bibr" rid="CR10">10</xref>], indicating a GHSR-independent mechanism of action, although a receptor for UAG remains to be discovered. Recently, we have also shown that UAG infusion in obese mice causes insulin-sensitizing effects [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p>Vascular complications are the major source of morbidity and mortality among patients with diabetes [<xref ref-type="bibr" rid="CR12">12</xref>]. Diabetes mellitus is associated with a 2- to 4-fold increase in rates of macrovascular disease [<xref ref-type="bibr" rid="CR13">13</xref>]. This is due to macrophage accumulation in the vascular wall and subsequent secretion of multiple proinflammatory growth factors and cytokines, a very important step in the pathological mechanism causing atherosclerosis [<xref ref-type="bibr" rid="CR14">14</xref>].</p><p>Monocytes and monocyte-derived cells are important in detecting and repairing vascular damage, in particular by producing proangiogenic factors which promote neovascularization and endothelial repair. These vessel-protective cells have previously been indicated as myeloid EPC [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>], but are now more accurately termed pro-angiogenic cells or circulating angiogenic cells (CAC). We will use the latter term throughout this study. CAC are involved in restoration of vascular homeostasis in diabetics. Monocyte differentiation and function in patients with diabetes is altered by metabolic conditions, resulting in the decreased ability of these cells to participate in vascular maintenance and repair [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>]. Data from recent experiments on CAC suggest that UAG may beneficially impact the vascular remodeling process which is known to be impaired in type 2 diabetes patients [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>].</p><p>The aims of the current study are to extend the findings of Togliatto et al. by examining the dose and time-dependent effects of in vivo UAG treatment on in vitro differentiation of isolated monocytes into CAC using different protocols, and into their presumed non-protective counterparts, macrophages. To do this, we first examined the effects of a short-term, i.e. overnight infusion of UAG at 3 and 10&#x000a0;&#x000b5;g/kg/h in T2D patients on differentiation of peripheral blood monocytes into CAC and macrophages. Since long-term UAG treatment of humans is not ethically feasible, we infused lean and obese mice with vehicle or UAG at 10&#x000a0;&#x000b5;g/kg/h for 4&#x000a0;weeks and examined their effect on differentiation of CAC from bone marrow monocyte progenitors.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study drug</title><p>UAG was obtained from Bachem AG, Hauptstrasse 144, Bubendorf CH-4416, Switzerland. UAG was delivered as lyophilized powder (vials containing 5&#x000a0;mg of drug) and stored as indicated by the manufacturer. The same peptide preparation was used for both animal and human experiments.</p></sec></sec><sec id="Sec4"><title>Human peripheral blood mononuclear cell cultures</title><sec id="Sec5"><title>Study design</title><p>This study is a single-center, investigator-initiated, double blind and placebo-controlled randomized study [<xref ref-type="bibr" rid="CR9">9</xref>]. The study was conducted in Erasmus University Medical Center Rotterdam after approval by the local IRB. All subjects gave their written informed consent before enrollment. The study included three overnight hospital admissions. During these three admissions, all subjects received either placebo, or UAG at 3 or 10&#x000a0;&#x003bc;g/kg/h in randomized order as a continuous infusion via an indwelling catheter as described below. A washout period of at least 1&#x000a0;week was used between the different treatment periods.</p><p>Placebo or UAG was continuously infused for 15&#x000a0;h from 22:00&#x000a0;h until 13:00&#x000a0;h the next day. At 8:00&#x02013;8:15&#x000a0;h the following morning, a standard breakfast meal (SBM) was served: 714&#x000a0;kcal (46% fat, 17% proteins, 37% carbohydrates). Before the start of each infusion period a continuous glucose monitor (iPro2, Medtronic trading, The Netherlands) was inserted to measure the subcutaneous interstitial blood glucose [<xref ref-type="bibr" rid="CR22">22</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref>].</p><p>Blood samples for isolating monocyte progenitors were collected before (16:00) and after (the next day at 14:00) the infusion period.</p></sec><sec id="Sec6"><title>Subjects</title><p>Eight subjects were enrolled (2 females&#x02013;6 males; mean age 53&#x000a0;years (range 31&#x02013;65 years). Mean body mass index (BMI) was 31.5&#x000a0;kg/m<sup>2</sup>, range 26&#x02013;40.1&#x000a0;kg/m<sup>2</sup>. All subjects were diagnosed with type 2 diabetes for at least 3&#x000a0;months prior to enrollment. Mean glycosylated hemoglobin levels (HbA1c) were 49 (41&#x02013;55)&#x000a0;mmol/mol [6.6 (5.9&#x02013;7.2)%]. Exclusion criteria were a history or presence of long-term type 2 diabetes complications; clinically significant abnormalities in laboratory evaluation at screening, and the use of systemic corticosteroids within 60&#x000a0;days prior to screening.</p><p>Four of eight patients were medicated with statins and two with antihypertensive drugs. All patients were being treated with metformin that was stopped 1&#x000a0;day prior to the start of each treatment period.</p></sec><sec id="Sec7"><title>Peripheral blood mononuclear cell cultures</title><p>Peripheral blood mononuclear cells (PBMC) were obtained by density gradient centrifugation (Ficoll-Paque PLUS, GE Healthcare 17-1440-03) of 50&#x000a0;ml of peripheral blood collected in sodium heparin tubes. CAC, also called early endothelial progenitor cells (EPC) or myeloid EPC, were cultured according to two different protocols as described by Murohara et al. and by Asahara et al. [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. These cultures are referred to as Toyo-CAC and EBM-CAC, respectively.</p><p>In both cultures, PBMC were plated in triplicate at a density of 2&#x000a0;&#x000d7;&#x000a0;10<sup>6</sup>&#x000a0;cells/ml/well in 24-well plates (Nunc) coated with 10&#x000a0;&#x003bc;g/ml of human fibronectin (Sigma). For Toyo-CAC, cells were cultured in M199 medium supplemented with 10% FCS, 0.05&#x000a0;mg/ml bovine pituitary extract (Invitrogen), 10,000&#x000a0;U&#x000a0;penicillin/ml, 10,000&#x000a0;U&#x000a0;streptomycin/ml (Lonza DE17-602E), and 10&#x000a0;units/ml heparin (Leo Pharma BV) at 37&#x000a0;&#x000b0;C and 5% CO<sub>2</sub>. For EBM-CAC, cells were cultured in EBM-2&#x000a0;+&#x000a0;EGM-2 (Lonza 3156; 4176) at 37&#x000a0;&#x000b0;C and 5% CO<sub>2</sub>. After 7&#x000a0;days of culture, Toyo-CAC and EBM-CAC cultures were washed profusely with PBS to retain only the adherent spindle-shaped cells. Cells were then fixed with paraformaldehyde (PFA, 4%) for 15&#x000a0;m at room temperature.</p><p>To generate human macrophages from monocytes under similar conditions, total PBMC were cultured in triplicate at a density of 1&#x000a0;x&#x000a0;10<sup>6</sup>&#x000a0;cells/well at 37&#x000a0;&#x000b0;C and 5% CO<sub>2</sub> in 24-well plates for 7&#x000a0;days in RPMI (25&#x000a0;mM Hepes, with Ultraglutamin-1) supplemented with human AB serum (Lonza 14-490E), 10,000&#x000a0;U&#x000a0;penicillin/ml, 10,000&#x000a0;U&#x000a0;streptomycin/ml (Lonza DE17-602E), and 10% M-CSF-containing conditioned medium from Ladmac cells [<xref ref-type="bibr" rid="CR28">28</xref>]. Fresh growth factor (100&#x000a0;&#x003bc;l) was added to each well on days 3 and 6. At day 7, plates were centrifuged at 1200&#x000a0;rpm for 3&#x000a0;min at 4&#x000a0;&#x000b0;C and cells were fixed with PFA (4%).</p><p>The quantification of cultures was performed fluorometrically on the basis of DNA content as assessed by propidum iodide staining [<xref ref-type="bibr" rid="CR29">29</xref>]. Briefly, wells were incubated with 20&#x000a0;&#x003bc;l propidium iodide (4&#x000a0;&#x003bc;l/ml; Sigma). After 10&#x000a0;min the fluorescence intensity was measured using a FLUOstar Optima plate reader (BMG Labtech, Ortenberg, Germany). Interpolation on a standard curve of PBMC was used to determine absolute cell numbers.</p></sec><sec id="Sec8"><title>Differentiation of CAC from bone marrow of lean and obese mice infused with UAG</title><p>C57BL/6 mice (10&#x000a0;week, male; Charles River Laboratories, Maastricht, The Netherlands) were maintained at 12:12&#x000a0;h light: dark, 21&#x000a0;&#x000b0;C, with free access to food and water. Normal (ND) and high fat (HFD) diets were from special diets services (Tecnilab-BMI, Someren, The Netherlands; product code 801722, 9%&#x000a0;kcal from fat, 69% from carbohydrate, 22% from protein) and ABDiets (Woerden, The Netherlands; 41%&#x000a0;kcal from fat, 40%&#x000a0;kcal from carbohydrate, 19%&#x000a0;kcal from protein), respectively. Animal experiments were performed with the approval of the Animal Ethics Committee at Erasmus MC (approval code: EMC2050). Mice were implanted with subcutaneous Alzet 1004 mini-osmotic pumps (Durect Corp., Cupertino, CA, USA) containing saline or UAG. UAG was infused at 10&#x000a0;&#x000b5;g/kg/h. Mice were split into two groups 2&#x000a0;weeks after pump implantation (n&#x000a0;=&#x000a0;3 for each of the 4 experimental groups), either continuing to receive the ND or given free access to the HFD, as previously described [<xref ref-type="bibr" rid="CR11">11</xref>]. At the end of the 4&#x000a0;week infusion period, bone marrow was collected from the femurs and tibiae, and culture of CAC/endothelial progenitor cells was performed as previously described [<xref ref-type="bibr" rid="CR30">30</xref>].</p><p>Weight and food intake were recorded 1&#x000a0;week before and weekly during the period of treatment. Data on weight, fat mass, glucose and insulin levels in these mice are described in Delhanty et al. [<xref ref-type="bibr" rid="CR11">11</xref>].</p></sec></sec><sec id="Sec9"><title>Results</title><sec id="Sec10"><title>Assessment of dose-dependent effects of UAG in humans</title><p>Baseline values of generated EBM-CAC, Toyo-CAC and macrophages are shown in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>, representing the retrieval of these cell types from cultures of PBMC obtained before the initiation of treatment. In both types of CAC cultures as well as in the macrophage cultures, a significant degree of variation was observed with respect to the absolute number of CAC and macrophages retrieved. This variation occurred not only between different patients, but also among different samples from the same patients obtained at different visits. Baseline culture results from some patients were relatively consistent, while results from others showed high degrees of variation, suggesting a strong influence of variable patient conditions upon admission. Furthermore, cells from some patients showed a virtually complete inability to generate either type of CAC and/or macrophages. For instance, cells from patient #7 generated virtually no EBM-CAC and macrophages, while Toyo-CAC could be readily measured. Another patient #2 generated virtually no Toyo-CAC or macrophages, but EBM-CAC could be shown, though at variable levels. These baseline findings also indicate that both types of CAC cultures and macrophage cultures measure essentially distinct parameters. This is confirmed by a correlation analysis of the culture yields before and after treatment (Figs.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>, <xref rid="Fig3" ref-type="fig">3</xref>). This shows that a significant correlation exists only between the quantity of EBM-CAC and macrophages at baseline (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b), but this correlation is lost after treatment with UAG (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>b).<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Baseline values for the generation of Toyo-CAC, EBM-CAC, and macrophages. PBMC were isolated from patients at admission, before treatment, and cultured under different conditions to generate EBM-CAC (<bold>a</bold>), Toyo-CAC (<bold>b</bold>), or macrophages (<bold>c</bold>). Each of the three data-points per patient represents the average of three replicate wells</p></caption><graphic xlink:href="13098_2017_239_Fig1_HTML" id="MO1"/></fig>
<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Correlation between EBM-CAC, Toyo-CAC and macrophage baseline culture yields. Outcomes of EBM-CAC, Toyo-CAC and macrophage cultures were correlated. A significant correlation was observed only between EBM-CAC and macrophage cultures (<bold>b</bold>), but not between the two types of CAC cultures (<bold>a</bold>), or the Toyo-CAC and macrophages (<bold>c</bold>)</p></caption><graphic xlink:href="13098_2017_239_Fig2_HTML" id="MO2"/></fig>
<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Correlation between EBM-CAC, Toyo-CAC and macrophage culture yields after UAG treatment. Outcomes of EBM-CAC, Toyo-CAC and macrophage cultures from PBMC obtained after treatment with UAG were correlated. No significant correlation was observed between the two types of CAC cultures (<bold>a</bold>), between EBM-CAC and macrophage cultures (<bold>b</bold>), or the Toyo-CAC and macrophages (<bold>c</bold>)</p></caption><graphic xlink:href="13098_2017_239_Fig3_HTML" id="MO3"/></fig>
</p><p>The effect of treatment of patients with 3 or 10&#x000a0;&#x000b5;g&#x000a0;UAG/kg/h on CAC and macrophage numbers is shown graphically for each patient in Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>. Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> indicates the quantification of these changes, expressed as mean cell count normalized to the mean pre-treatment value. Clearly, the treatment effects were very diverse, and major differences between and among patients were observed. Even the direction of change differed, although for both types of CAC cultures high pre-treatment measurements tended to decrease upon treatment, while low pre-treatment values increased (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a, b). Only in two conditions were statistically significant differences observed between pre- and post-treatment samples: treatment with 10&#x000a0;&#x000b5;g/kg/h UAG reduced EBM-CAC to 70% (p&#x000a0;=&#x000a0;0.045), while treatment with 3&#x000a0;&#x000b5;g/kg/h UAG caused reduction of Toyo-CAC to 60% (p&#x000a0;=&#x000a0;0.038) (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Enigmatically, however, in both cases treatment with the lower or higher concentration, respectively, did not show a similar trend.<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Treatment-related changes in the quantity of obtained EBM-CAC, Toyo-CAC and macrophages. For each patient, the yields of EBM-CAC (<bold>a</bold>), Toyo-CAC (<bold>b</bold>) and macrophages (<bold>c</bold>) derived from PBMC isolated from pre- and post-treatment samples are shown. Each data point represents the average of three individual wells. Quantitative analysis of these data is shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>
</p></caption><graphic xlink:href="13098_2017_239_Fig4_HTML" id="MO4"/></fig>
<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Treatment-related changes in the yield of CAC and macrophages</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Culture</th><th align="left">Treatment</th><th align="left">Normalized mean cell count post-tx<sup>a</sup>
</th><th align="left">
<italic>p</italic> value<sup>b</sup>
</th></tr></thead><tbody><tr><td align="left" rowspan="3">EBM-CAC</td><td align="left">Placebo</td><td char="&#x000b1;" align="char">1.1&#x000a0;&#x000b1;&#x000a0;1.2</td><td char="." align="char">0.219</td></tr><tr><td align="left">3&#x000a0;&#x000b5;g/kg/h</td><td char="&#x000b1;" align="char">1.0&#x000a0;&#x000b1;&#x000a0;1.0</td><td char="." align="char">0.938</td></tr><tr><td align="left">10&#x000a0;&#x000b5;g/kg/h</td><td char="&#x000b1;" align="char">0.7&#x000a0;&#x000b1;&#x000a0;0.6</td><td char="." align="char">
<italic>0.045</italic>
</td></tr><tr><td align="left" rowspan="3">Toyo-CAC</td><td align="left">Placebo</td><td char="&#x000b1;" align="char">0.8&#x000a0;&#x000b1;&#x000a0;0.7</td><td char="." align="char">0.507</td></tr><tr><td align="left">3&#x000a0;&#x000b5;g/kg/h</td><td char="&#x000b1;" align="char">0.6&#x000a0;&#x000b1;&#x000a0;0.4</td><td char="." align="char">
<italic>0.038</italic>
</td></tr><tr><td align="left">10&#x000a0;&#x000b5;g/kg/h</td><td char="&#x000b1;" align="char">1.2&#x000a0;&#x000b1;&#x000a0;0.8</td><td char="." align="char">0.780</td></tr><tr><td align="left" rowspan="3">macrophages</td><td align="left">Placebo</td><td char="&#x000b1;" align="char">0.6&#x000a0;&#x000b1;&#x000a0;0.5</td><td char="." align="char">0.053</td></tr><tr><td align="left">3&#x000a0;&#x000b5;g/kg/h</td><td char="&#x000b1;" align="char">0.9&#x000a0;&#x000b1;&#x000a0;0.4</td><td char="." align="char">0.617</td></tr><tr><td align="left">10&#x000a0;&#x000b5;g/kg/h</td><td char="&#x000b1;" align="char">1.0&#x000a0;&#x000b1;&#x000a0;0.8</td><td char="." align="char">0.097</td></tr></tbody></table><table-wrap-foot><p>For each patient, the baseline values of that specific visit were compared with culture yields after treatment</p><p>
<sup>a</sup>The mean obtained cell number of pre-tx samples was set at 1; mean post-tx number is expressed relative to this &#x000b1;&#x000a0;SD</p><p>
<sup>b</sup>Significance was determined by paired t test</p></table-wrap-foot></table-wrap>
</p><p>For the macrophage cultures, the yield of cells post-treatment tended to decrease in all cases including placebo treatment (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>c), although single measurements showing increased macrophage yield prevented attainment of statistical significance.</p></sec><sec id="Sec11"><title>Assessment of long-term treatment with UAG in mice</title><p>Since short-term treatment of humans with UAG had relatively inconsistent effects, we wanted to determine if longer-term treatment might change this outcome. However, for ethical reasons, long-term treatment of humans is not yet possible. Therefore we used a model of diet-induced obesity in mice. The HFD caused a significant increase in fat mass which was prevented by infusion of UAG, as described in our previous publication [<xref ref-type="bibr" rid="CR11">11</xref>]. In that study, we also found that UAG infusion prevented the glucose intolerance and insulin resistance that accompanied this increase in fat mass. Testing the effect of 4&#x000a0;weeks of UAG infusion on the differentiation of CAC from bone marrow progenitors showed that infusion of UAG in both ND-fed lean mice as well as mice given a short-term HFD caused a consistent, significant increase in recovery of CAC from bone marrow cultures (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>).<fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>Effect of UAG infusion endothelial progenitor cell recovery from murine bone marrow cell cultures. Mice infused for 4&#x000a0;weeks with UAG fed either a normal or high fat diet during the last 2&#x000a0;weeks of treatment. Bone marrow was then isolated and cultured to generate endothelial progenitor cells (aka. CAC). The data represents the average recovery of cells in three replicate wells of bone marrow cells from three different mice. (*p&#x000a0;&#x0003c;&#x000a0;0.05; **p&#x000a0;&#x0003c;&#x000a0;0.01 versus ND saline group; ANOVA)</p></caption><graphic xlink:href="13098_2017_239_Fig5_HTML" id="MO5"/></fig>
</p></sec></sec><sec id="Sec12"><title>Discussion</title><p>Previous studies have indicated that T2D is associated with reduced numbers of monocyte-derived CAC [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>]. Reduced numbers and impaired function of these monocytes in diabetes increased atherosclerosis. Endothelial injury is thought to represent an important step in the initiation and progression of atherosclerotic vascular disease [<xref ref-type="bibr" rid="CR31">31</xref>]. As mentioned earlier, UAG may have beneficial effects on the vascular remodeling process in T2D patients [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Early CAC play a very important role in this process. To further investigate the effect of UAG treatment on CAC, and compare this to macrophage-forming potential, we performed two in vivo studies: a short-term study to assess dose-dependency of UAG effects in T2D patients; and a study to investigate the effects of long-term UAG treatment in mice with decreased insulin sensitivity induced by diet-induced obesity. In humans, we studied the effects of a continuous overnight infusion of UAG or placebo in eight overweight mild type 2 diabetics. We found that short-term infusion of UAG had significant suppressive effects on CAC number at different doses, but this was dependent on differentiation procedure. Our findings are not consistent with those of Togliatto who found that systemic overnight administration of UAG at 3&#x000a0;&#x000b5;g/kg/h (our low dose) prevented diabetes-induced EPC decrease, and increased endothelial progenitor cell mobilization in individuals with T2D [<xref ref-type="bibr" rid="CR20">20</xref>]. It is currently unknown how UAG interferes with the differentiation of the cells. There is evidence for an Akt-eNOS-MMP9-sKitL pathway that could be involved in release of EPCs into the circulation [<xref ref-type="bibr" rid="CR20">20</xref>]. The most important explanation for these conflicting results is the heterogeneity in our population. The variation, shown in Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>c, within and among patients is too large to draw firm conclusions; in general, there is no clear effect of the treatment, other than a slight decrease rather than the expected increase of CAC numbers following UAG treatment. An important difference between the studies was that the T2D subjects described in the paper of Togliatto et al. had not been medicated [<xref ref-type="bibr" rid="CR20">20</xref>]. They were treated with diet alone. In contrast, four of our eight patients were on statins and two used antihypertensive medication. Davignon et al. [<xref ref-type="bibr" rid="CR32">32</xref>] showed that statins generate potent anti-inflammatory actions and can also improve dysfunctional EPC populations in vitro [<xref ref-type="bibr" rid="CR33">33</xref>&#x02013;<xref ref-type="bibr" rid="CR36">36</xref>]. A potential molecular mechanism of statin action on EPC might involve the PI3&#x000a0;K/Akt pathway [<xref ref-type="bibr" rid="CR34">34</xref>] and the inhibition of apoptosis [<xref ref-type="bibr" rid="CR37">37</xref>]. In our population four patients received statin treatment (patient 1, 4, 5 and 8). The statin treatment was put on hold 1&#x000a0;day before testing. With their long half- life, especially of atorvastatin, we can still expect a carry-over effect during the UAG administration in our study. However, a sub-analysis of the statin-using group showed no significant differences between this group and the subjects that did not use statins. This may be caused by the large inter- and intra-individual differences and the small group size. Other studies show that the angiotensin-converting enzyme (ACE) inhibitors such as ramipril [<xref ref-type="bibr" rid="CR38">38</xref>] and angiotensin II (AT II) inhibitors, like valsartan [<xref ref-type="bibr" rid="CR39">39</xref>] can increase EPC levels in patients, probably interfering with the CD26/dipeptidyl peptidase IV system. One patient used ramipril, but this treatment was not associated with an increase in the number of circulating CAC. Furthermore, all patients were being treated with metformin, that was stopped 1&#x000a0;day prior to the start of each treatment period. Chronic treatment with metformin in obese patients with T2D did not change ghrelin levels before and after start with metformin [<xref ref-type="bibr" rid="CR40">40</xref>]. Ida et al., showed in 12 RCTs that there were no significant differences in ghrelin levels [<xref ref-type="bibr" rid="CR41">41</xref>]. The effect of metformin on UAG is unknown. If there is an effect on UAG, it was similarly in all the patients because metformin was stopped at the same time in all patients. Another explanation for our inconclusive results is the notion that our population with a mean HbA1c of 49&#x000a0;mmol/mol (6.6%) was well regulated. Loomans et al. [<xref ref-type="bibr" rid="CR30">30</xref>] observed a significant inverse correlation between the number of circulating EPC and HbA1c levels in patients with type 1 diabetes. On average, this population had a 40% reduction in the circulating number of short term cultured EPC, and an HbA1c of more than 8% [<xref ref-type="bibr" rid="CR30">30</xref>]. These EPC were cultured as described by Murohara [<xref ref-type="bibr" rid="CR26">26</xref>], described in our study as Toyo-CAC. The question remains whether the number of CAC are affected in our mild diabetics. Loomans et al. obtained similar results in a hyperglycemic mouse model [<xref ref-type="bibr" rid="CR30">30</xref>]. In this study, it was found that HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibitors overcome the effects of hyperglycemia on EPC. Adding this Atorvastatin in vitro to bone marrow differentiation cultures increased the number of EPC and conversely decreased the number of macrophages. Interestingly, this study showed that statin treatment directly increases myeloid EPC generation in vitro from BM precursors derived from mice rendered diabetic by streptozotocin treatment.</p><p>In all human samples placebo treatment decreased the yields in macrophage cultures. Maybe this is due to the change of environment. For example the stress of a hospital visit may have caused lower numbers of macrophages. Pre-treatment samples were taken within 1&#x000a0;h after admission and it is known that stress and physical activity increase numbers of circulating leukocytes, including monocytes [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. Furthermore, the numbers of circulating cells, including monocytes and different populations of EPC, are known to be influenced by circadian variation [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. Since pre- and post-treatment collection of peripheral blood differ only by 3&#x000a0;h (i.e. 16:00 vs. 13:00&#x000a0;h), it is unlikely that this difference plays a significant role in the observed variability.</p><p>An explanation for the high degree of variation observed in the CAC and macrophage cultures can only be speculative at this point. Technical variation may add to the diversity, although we have reason to believe that this contribution is limited. As indicated above, we obtained a very consistent yield of CAC and/or macrophages in a number of pre-treatment samples from individual patients, and these values were acquired in cultures generated over several weeks and at different time points during the study. That leaves a potentially significant contribution of inter- and intra-individual differences induced by inborn as well as environmental conditions as the most likely reason for the observed variability in CAC and macrophage generation.</p><p>We have previously reported that a short-term high fat diet causes a doubling in abdominal white fat mass in mice, and significantly impairs insulin sensitivity and glucose tolerance [<xref ref-type="bibr" rid="CR11">11</xref>]. Using this model we showed that long-term (4&#x000a0;week) UAG infusion at 10&#x000a0;&#x000b5;g/kg/h blocked these effects. Utilizing mice from this study we here also assess the ability of bone marrow progenitors to differentiate into CAC in either vehicle or UAG infused lean or obese mice. Like Togliatto et al. we found that UAG caused an increase in recovery of CAC from differentiated bone marrow cell cultures in obese mice [<xref ref-type="bibr" rid="CR20">20</xref>]. However, we also find a similar effect in lean mice. In either diet condition, we observed no changes in the generation of macrophages from bone marrow precursors upon treatment with UAG, as reported in our previous study [<xref ref-type="bibr" rid="CR11">11</xref>]. These data might suggest that longer term treatment in humans may be necessary to observe consistent effects of UAG treatment on CAC, however additional studies are necessary, to confirm this.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ACE</term><def><p>angiotensin-converting enzyme</p></def></def-item><def-item><term>AG</term><def><p>acylated ghrelin</p></def></def-item><def-item><term>ATII</term><def><p>angiotensinII</p></def></def-item><def-item><term>BMI</term><def><p>body mass index</p></def></def-item><def-item><term>CAC</term><def><p>circulating angiogenic cells</p></def></def-item><def-item><term>EPC</term><def><p>endothelial progenitor cells</p></def></def-item><def-item><term>GH</term><def><p>growth hormone</p></def></def-item><def-item><term>GHSR1a</term><def><p>growth hormone secretagogue receptor</p></def></def-item><def-item><term>GOAT</term><def><p>ghrelin <italic>O</italic>-acyl transferase</p></def></def-item><def-item><term>HbA1c</term><def><p>glycosylated hemoglobin levels</p></def></def-item><def-item><term>HFD</term><def><p>high fat diet</p></def></def-item><def-item><term>HMG-CoA</term><def><p>3-hydroxy-3-methylglutaryl coenzyme A</p></def></def-item><def-item><term>ND</term><def><p>normal diet</p></def></def-item><def-item><term>PBMC</term><def><p>peripheral blood mononuclear cells</p></def></def-item><def-item><term>PFA</term><def><p>paraformaldehyde</p></def></def-item><def-item><term>SBM</term><def><p>standard breakfast meal</p></def></def-item><def-item><term>UAG</term><def><p>unacylated ghrelin</p></def></def-item></def-list></glossary><ack><title>Authors&#x02019; contributions</title><p>BO contributes to the design and the conduct of the study, interpretation of data and the writing process of the paper. PL, SN, AJL: participated in the writing of the manuscript. LB and PD analysis of the data and revision of the manuscript. All authors read and approved the final manuscript.</p><sec id="FPar1"><title>Acknowledgements</title><p>The authors want to thank S. Poldermans, E. van Eck, T. Iqbal, S. Michels and A. van Oudenaren for their splendid logistical and technical support.</p></sec><sec id="FPar2"><title>Competing interests</title><p>A J van der Lely is a scientific advisor, shareholder of Alize&#x000b4; Pharma. The other authors declare that they have no competing interests.</p></sec><sec id="FPar3"><title>Availability of data and materials</title><p>The datasets generated during and/or analysed during the current study are available from the authors upon reasonable request.</p></sec><sec id="FPar4"><title>Declarations</title><p>The study was conducted in Erasmus University Medical Center Rotterdam after approval by the local IRB.</p><p>Animal experiments were performed with the approval of the Animal Ethics Committee at Erasmus MC (approval code: EMC2050).</p></sec><sec id="FPar5"><title>Publisher&#x02019;s Note</title><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hosoda</surname><given-names>H</given-names></name><name><surname>Kojima</surname><given-names>M</given-names></name><name><surname>Kangawa</surname><given-names>K</given-names></name></person-group><article-title>Biological, physiological, and pharmacological aspects of ghrelin</article-title><source>J Pharmacol Sci</source><year>2006</year><volume>100</volume><fpage>398</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1254/jphs.CRJ06002X</pub-id><pub-id pub-id-type="pmid">16612045</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broglio</surname><given-names>F</given-names></name><name><surname>Gottero</surname><given-names>C</given-names></name><name><surname>Prodam</surname><given-names>F</given-names></name><name><surname>Gauna</surname><given-names>C</given-names></name><name><surname>Muccioli</surname><given-names>G</given-names></name><name><surname>Papotti</surname><given-names>M</given-names></name><etal/></person-group><article-title>Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans</article-title><source>J Clin Endocrinol Metab</source><year>2004</year><volume>89</volume><fpage>3062</fpage><lpage>3065</lpage><pub-id pub-id-type="doi">10.1210/jc.2003-031964</pub-id><pub-id pub-id-type="pmid">15181099</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muller</surname><given-names>TD</given-names></name><name><surname>Nogueiras</surname><given-names>R</given-names></name><name><surname>Andermann</surname><given-names>ML</given-names></name><name><surname>Andrews</surname><given-names>ZB</given-names></name><name><surname>Anker</surname><given-names>SD</given-names></name><name><surname>Argente</surname><given-names>J</given-names></name><etal/></person-group><article-title>Ghrelin</article-title><source>Mol Metab</source><year>2015</year><volume>4</volume><fpage>437</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1016/j.molmet.2015.03.005</pub-id><pub-id pub-id-type="pmid">26042199</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kojima</surname><given-names>M</given-names></name><name><surname>Hosoda</surname><given-names>H</given-names></name><name><surname>Date</surname><given-names>Y</given-names></name><name><surname>Nakazato</surname><given-names>M</given-names></name><name><surname>Matsuo</surname><given-names>H</given-names></name><name><surname>Kangawa</surname><given-names>K</given-names></name></person-group><article-title>Ghrelin is a growth-hormone-releasing acylated peptide from stomach</article-title><source>Nature</source><year>1999</year><volume>402</volume><fpage>656</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1038/45230</pub-id><pub-id pub-id-type="pmid">10604470</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kojima</surname><given-names>M</given-names></name><name><surname>Kangawa</surname><given-names>K</given-names></name></person-group><article-title>Ghrelin: more than endogenous growth hormone secretagogue</article-title><source>Ann NY Acad Sci</source><year>2010</year><volume>1200</volume><fpage>140</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2010.05516.x</pub-id><pub-id pub-id-type="pmid">20633142</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gauna</surname><given-names>C</given-names></name><name><surname>van de Zande</surname><given-names>B</given-names></name><name><surname>van Kerkwijk</surname><given-names>A</given-names></name><name><surname>Themmen</surname><given-names>AP</given-names></name><name><surname>van der Lely</surname><given-names>AJ</given-names></name><name><surname>Delhanty</surname><given-names>PJ</given-names></name></person-group><article-title>Unacylated ghrelin is not a functional antagonist but a full agonist of the type 1a growth hormone secretagogue receptor (GHS-R)</article-title><source>Mol Cell Endocrinol</source><year>2007</year><volume>274</volume><fpage>30</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.mce.2007.05.010</pub-id><pub-id pub-id-type="pmid">17601657</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broglio</surname><given-names>F</given-names></name><name><surname>Benso</surname><given-names>A</given-names></name><name><surname>Gottero</surname><given-names>C</given-names></name><name><surname>Prodam</surname><given-names>F</given-names></name><name><surname>Gauna</surname><given-names>C</given-names></name><name><surname>Filtri</surname><given-names>L</given-names></name><etal/></person-group><article-title>Non-acylated ghrelin does not possess the pituitaric and pancreatic endocrine activity of acylated ghrelin in humans</article-title><source>J Endocrinol Invest</source><year>2003</year><volume>26</volume><fpage>192</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1007/BF03345156</pub-id><pub-id pub-id-type="pmid">12809167</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gauna</surname><given-names>C</given-names></name><name><surname>Meyler</surname><given-names>FM</given-names></name><name><surname>Janssen</surname><given-names>J</given-names></name><name><surname>Delhanty</surname><given-names>PJD</given-names></name><name><surname>Abribat</surname><given-names>T</given-names></name><name><surname>Van Koetsveld</surname><given-names>P</given-names></name><etal/></person-group><article-title>Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity</article-title><source>J Clin Endocrinol Metab</source><year>2004</year><volume>89</volume><fpage>5035</fpage><lpage>5042</lpage><pub-id pub-id-type="doi">10.1210/jc.2004-0363</pub-id><pub-id pub-id-type="pmid">15472202</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozcan</surname><given-names>B</given-names></name><name><surname>Neggers</surname><given-names>SJ</given-names></name><name><surname>Miller</surname><given-names>AR</given-names></name><name><surname>Yang</surname><given-names>HC</given-names></name><name><surname>Lucaites</surname><given-names>V</given-names></name><name><surname>Abribat</surname><given-names>T</given-names></name><etal/></person-group><article-title>Does des-acyl ghrelin improve glycemic control in obese diabetic subjects by decreasing acylated ghrelin levels?</article-title><source>Eur J Endocrinol</source><year>2014</year><volume>170</volume><fpage>799</fpage><lpage>807</lpage><pub-id pub-id-type="doi">10.1530/EJE-13-0347</pub-id><pub-id pub-id-type="pmid">23864339</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delhanty</surname><given-names>PJ</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Visser</surname><given-names>JA</given-names></name><name><surname>van Kerkwijk</surname><given-names>A</given-names></name><name><surname>Huisman</surname><given-names>M</given-names></name><name><surname>van Ijcken</surname><given-names>WF</given-names></name><etal/></person-group><article-title>Unacylated ghrelin rapidly modulates lipogenic and insulin signaling pathway gene expression in metabolically active tissues of GHSR deleted mice</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><fpage>e11749</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0011749</pub-id><pub-id pub-id-type="pmid">20668691</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delhanty</surname><given-names>PJ</given-names></name><name><surname>Huisman</surname><given-names>M</given-names></name><name><surname>Baldeon-Rojas</surname><given-names>LY</given-names></name><name><surname>van den Berge</surname><given-names>I</given-names></name><name><surname>Grefhorst</surname><given-names>A</given-names></name><name><surname>Abribat</surname><given-names>T</given-names></name><etal/></person-group><article-title>Des-acyl ghrelin analogs prevent high-fat-diet-induced dysregulation of glucose homeostasis</article-title><source>FASEB J</source><year>2013</year><volume>27</volume><fpage>1690</fpage><lpage>1700</lpage><pub-id pub-id-type="doi">10.1096/fj.12-221143</pub-id><pub-id pub-id-type="pmid">23299855</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fonseca</surname><given-names>V</given-names></name><name><surname>Desouza</surname><given-names>C</given-names></name><name><surname>Asnani</surname><given-names>S</given-names></name><name><surname>Jialal</surname><given-names>I</given-names></name></person-group><article-title>Nontraditional risk factors for cardiovascular disease in diabetes</article-title><source>Endocr Rev</source><year>2004</year><volume>25</volume><fpage>153</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1210/er.2002-0034</pub-id><pub-id pub-id-type="pmid">14769830</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beckman</surname><given-names>JA</given-names></name><name><surname>Creager</surname><given-names>MA</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name></person-group><article-title>Diabetes and atherosclerosis: epidemiology, pathophysiology, and management</article-title><source>JAMA</source><year>2002</year><volume>287</volume><fpage>2570</fpage><lpage>2581</lpage><pub-id pub-id-type="doi">10.1001/jama.287.19.2570</pub-id><pub-id pub-id-type="pmid">12020339</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanter</surname><given-names>JE</given-names></name><name><surname>Bornfeldt</surname><given-names>KE</given-names></name></person-group><article-title>Inflammation and diabetes-accelerated atherosclerosis: myeloid cell mediators</article-title><source>Trends Endocrinol Metab</source><year>2013</year><volume>24</volume><fpage>137</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1016/j.tem.2012.10.002</pub-id><pub-id pub-id-type="pmid">23153419</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prater</surname><given-names>DN</given-names></name><name><surname>Case</surname><given-names>J</given-names></name><name><surname>Ingram</surname><given-names>DA</given-names></name><name><surname>Yoder</surname><given-names>MC</given-names></name></person-group><article-title>Working hypothesis to redefine endothelial progenitor cells</article-title><source>Leukemia</source><year>2007</year><volume>21</volume><fpage>1141</fpage><lpage>1149</lpage><pub-id pub-id-type="doi">10.1038/sj.leu.2404676</pub-id><pub-id pub-id-type="pmid">17392816</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Timmermans</surname><given-names>F</given-names></name><name><surname>Plum</surname><given-names>J</given-names></name><name><surname>Yoder</surname><given-names>MC</given-names></name><name><surname>Ingram</surname><given-names>DA</given-names></name><name><surname>Vandekerckhove</surname><given-names>B</given-names></name><name><surname>Case</surname><given-names>J</given-names></name></person-group><article-title>Endothelial progenitor cells: identity defined?</article-title><source>J Cell Mol Med</source><year>2009</year><volume>13</volume><fpage>87</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1111/j.1582-4934.2008.00598.x</pub-id><pub-id pub-id-type="pmid">19067770</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tepper</surname><given-names>OM</given-names></name><name><surname>Galiano</surname><given-names>RD</given-names></name><name><surname>Capla</surname><given-names>JM</given-names></name><name><surname>Kalka</surname><given-names>C</given-names></name><name><surname>Gagne</surname><given-names>PJ</given-names></name><name><surname>Jacobowitz</surname><given-names>GR</given-names></name><etal/></person-group><article-title>Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures</article-title><source>Circulation</source><year>2002</year><volume>106</volume><fpage>2781</fpage><lpage>2786</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000039526.42991.93</pub-id><pub-id pub-id-type="pmid">12451003</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thum</surname><given-names>T</given-names></name><name><surname>Fraccarollo</surname><given-names>D</given-names></name><name><surname>Schultheiss</surname><given-names>M</given-names></name><name><surname>Froese</surname><given-names>S</given-names></name><name><surname>Galuppo</surname><given-names>P</given-names></name><name><surname>Widder</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Endothelial nitric oxide synthase uncoupling impairs endothelial progenitor cell mobilization and function in diabetes</article-title><source>Diabetes</source><year>2007</year><volume>56</volume><fpage>666</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.2337/db06-0699</pub-id><pub-id pub-id-type="pmid">17327434</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urbich</surname><given-names>C</given-names></name><name><surname>Dernbach</surname><given-names>E</given-names></name><name><surname>Rossig</surname><given-names>L</given-names></name><name><surname>Zeiher</surname><given-names>AM</given-names></name><name><surname>Dimmeler</surname><given-names>S</given-names></name></person-group><article-title>High glucose reduces cathepsin L activity and impairs invasion of circulating progenitor cells</article-title><source>J Mol Cell Cardiol</source><year>2008</year><volume>45</volume><fpage>429</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2008.06.004</pub-id><pub-id pub-id-type="pmid">18619973</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Togliatto</surname><given-names>G</given-names></name><name><surname>Trombetta</surname><given-names>A</given-names></name><name><surname>Dentelli</surname><given-names>P</given-names></name><name><surname>Baragli</surname><given-names>A</given-names></name><name><surname>Rosso</surname><given-names>A</given-names></name><name><surname>Granata</surname><given-names>R</given-names></name><etal/></person-group><article-title>Unacylated ghrelin rescues endothelial progenitor cell function in individuals with type 2 diabetes</article-title><source>Diabetes</source><year>2010</year><volume>59</volume><fpage>1016</fpage><lpage>1025</lpage><pub-id pub-id-type="doi">10.2337/db09-0858</pub-id><pub-id pub-id-type="pmid">20068135</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benso</surname><given-names>A</given-names></name><name><surname>St-Pierre</surname><given-names>DH</given-names></name><name><surname>Prodam</surname><given-names>F</given-names></name><name><surname>Gramaglia</surname><given-names>E</given-names></name><name><surname>Granata</surname><given-names>R</given-names></name><name><surname>van der Lely</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Metabolic effects of overnight continuous infusion of unacylated ghrelin in humans</article-title><source>Eur J Endocrinol</source><year>2012</year><volume>166</volume><fpage>911</fpage><lpage>916</lpage><pub-id pub-id-type="doi">10.1530/EJE-11-0982</pub-id><pub-id pub-id-type="pmid">22379116</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>NA</given-names></name><name><surname>Fain</surname><given-names>JA</given-names></name><name><surname>Braun</surname><given-names>B</given-names></name><name><surname>Chipkin</surname><given-names>SR</given-names></name></person-group><article-title>Continuous glucose monitoring in non-insulin-using individuals with type 2 diabetes: acceptability, feasibility, and teaching opportunities</article-title><source>Diabetes Technol Ther</source><year>2009</year><volume>11</volume><fpage>151</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1089/dia.2008.0053</pub-id><pub-id pub-id-type="pmid">19216684</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maia</surname><given-names>FF</given-names></name><name><surname>Araujo</surname><given-names>LR</given-names></name></person-group><article-title>Efficacy of continuous glucose monitoring system (CGMS) to detect postprandial hyperglycemia and unrecognized hypoglycemia in type 1 diabetic patients</article-title><source>Diabetes Res Clin Pract</source><year>2007</year><volume>75</volume><fpage>30</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.diabres.2006.05.009</pub-id><pub-id pub-id-type="pmid">16806560</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>HR</given-names></name><name><surname>Rayman</surname><given-names>G</given-names></name><name><surname>Lewis</surname><given-names>K</given-names></name><name><surname>Kelly</surname><given-names>S</given-names></name><name><surname>Johal</surname><given-names>B</given-names></name><name><surname>Duffield</surname><given-names>K</given-names></name><etal/></person-group><article-title>Effectiveness of continuous glucose monitoring in pregnant women with diabetes: randomised clinical trial</article-title><source>BMJ (Clinical research ed)</source><year>2008</year><volume>337</volume><fpage>a1680</fpage><pub-id pub-id-type="doi">10.1136/bmj.a1680</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanenberg</surname><given-names>R</given-names></name><name><surname>Bode</surname><given-names>B</given-names></name><name><surname>Lane</surname><given-names>W</given-names></name><name><surname>Levetan</surname><given-names>C</given-names></name><name><surname>Mestman</surname><given-names>J</given-names></name><name><surname>Harmel</surname><given-names>AP</given-names></name><etal/></person-group><article-title>Use of the continuous glucose monitoring system to guide therapy in patients with insulin-treated diabetes: a randomized controlled trial</article-title><source>Mayo Clin proc</source><year>2004</year><volume>79</volume><fpage>1521</fpage><lpage>1526</lpage><pub-id pub-id-type="doi">10.4065/79.12.1521</pub-id><pub-id pub-id-type="pmid">15595336</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murohara</surname><given-names>T</given-names></name><name><surname>Ikeda</surname><given-names>H</given-names></name><name><surname>Duan</surname><given-names>J</given-names></name><name><surname>Shintani</surname><given-names>S</given-names></name><name><surname>Sasaki</surname><given-names>K</given-names></name><name><surname>Eguchi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization</article-title><source>J Clin Invest</source><year>2000</year><volume>105</volume><fpage>1527</fpage><lpage>1536</lpage><pub-id pub-id-type="doi">10.1172/JCI8296</pub-id><pub-id pub-id-type="pmid">10841511</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asahara</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Masuda</surname><given-names>H</given-names></name><name><surname>Kalka</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Iwaguro</surname><given-names>H</given-names></name><etal/></person-group><article-title>VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells</article-title><source>EMBO J</source><year>1999</year><volume>18</volume><fpage>3964</fpage><lpage>3972</lpage><pub-id pub-id-type="doi">10.1093/emboj/18.14.3964</pub-id><pub-id pub-id-type="pmid">10406801</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sklar</surname><given-names>MD</given-names></name><name><surname>Tereba</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>BD</given-names></name><name><surname>Walker</surname><given-names>WS</given-names></name></person-group><article-title>Transformation of mouse bone marrow cells by transfection with a human oncogene related to c-myc is associated with the endogenous production of macrophage colony stimulating factor 1</article-title><source>J Cell Physiol</source><year>1985</year><volume>125</volume><fpage>403</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1002/jcp.1041250307</pub-id><pub-id pub-id-type="pmid">3877730</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wrobel</surname><given-names>K</given-names></name><name><surname>Claudio</surname><given-names>E</given-names></name><name><surname>Segade</surname><given-names>F</given-names></name><name><surname>Ramos</surname><given-names>S</given-names></name><name><surname>Lazo</surname><given-names>PS</given-names></name></person-group><article-title>Measurement of cytotoxicity by propidium iodide staining of target cell DNA. Application to the quantification of murine TNF-alpha</article-title><source>J Immunol Methods</source><year>1996</year><volume>189</volume><fpage>243</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1016/0022-1759(95)00253-7</pub-id><pub-id pub-id-type="pmid">8613675</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loomans</surname><given-names>CJ</given-names></name><name><surname>van Haperen</surname><given-names>R</given-names></name><name><surname>Duijs</surname><given-names>JM</given-names></name><name><surname>Verseyden</surname><given-names>C</given-names></name><name><surname>de Crom</surname><given-names>R</given-names></name><name><surname>Leenen</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>Differentiation of bone marrow-derived endothelial progenitor cells is shifted into a proinflammatory phenotype by hyperglycemia</article-title><source>Mol Med</source><year>2009</year><volume>15</volume><fpage>152</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.2119/molmed.2009.00032</pub-id><pub-id pub-id-type="pmid">19295918</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waltenberger</surname><given-names>J</given-names></name></person-group><article-title>Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications</article-title><source>Cardiovasc Res</source><year>2001</year><volume>49</volume><fpage>554</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1016/S0008-6363(00)00228-5</pub-id><pub-id pub-id-type="pmid">11166268</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davignon</surname><given-names>J</given-names></name></person-group><article-title>Beneficial cardiovascular pleiotropic effects of statins</article-title><source>Circulation</source><year>2004</year><volume>109</volume><fpage>III39</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">15198965</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llevadot</surname><given-names>J</given-names></name><name><surname>Murasawa</surname><given-names>S</given-names></name><name><surname>Kureishi</surname><given-names>Y</given-names></name><name><surname>Uchida</surname><given-names>S</given-names></name><name><surname>Masuda</surname><given-names>H</given-names></name><name><surname>Kawamoto</surname><given-names>A</given-names></name><etal/></person-group><article-title>HMG-CoA reductase inhibitor mobilizes bone marrow&#x02013;derived endothelial progenitor cells</article-title><source>J Clin Invest</source><year>2001</year><volume>108</volume><fpage>399</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1172/JCI200113131</pub-id><pub-id pub-id-type="pmid">11489933</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dimmeler</surname><given-names>S</given-names></name><name><surname>Aicher</surname><given-names>A</given-names></name><name><surname>Vasa</surname><given-names>M</given-names></name><name><surname>Mildner-Rihm</surname><given-names>C</given-names></name><name><surname>Adler</surname><given-names>K</given-names></name><name><surname>Tiemann</surname><given-names>M</given-names></name><etal/></person-group><article-title>HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway</article-title><source>J Clin Invest</source><year>2001</year><volume>108</volume><fpage>391</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1172/JCI200113152</pub-id><pub-id pub-id-type="pmid">11489932</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walter</surname><given-names>DH</given-names></name><name><surname>Rittig</surname><given-names>K</given-names></name><name><surname>Bahlmann</surname><given-names>FH</given-names></name><name><surname>Kirchmair</surname><given-names>R</given-names></name><name><surname>Silver</surname><given-names>M</given-names></name><name><surname>Murayama</surname><given-names>T</given-names></name><etal/></person-group><article-title>Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells</article-title><source>Circulation</source><year>2002</year><volume>105</volume><fpage>3017</fpage><lpage>3024</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000018166.84319.55</pub-id><pub-id pub-id-type="pmid">12081997</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gazzerro</surname><given-names>P</given-names></name><name><surname>Proto</surname><given-names>MC</given-names></name><name><surname>Gangemi</surname><given-names>G</given-names></name><name><surname>Malfitano</surname><given-names>AM</given-names></name><name><surname>Ciaglia</surname><given-names>E</given-names></name><name><surname>Pisanti</surname><given-names>S</given-names></name><etal/></person-group><article-title>Pharmacological actions of statins: a critical appraisal in the management of cancer</article-title><source>Pharmacol Rev</source><year>2012</year><volume>64</volume><fpage>102</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1124/pr.111.004994</pub-id><pub-id pub-id-type="pmid">22106090</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urbich</surname><given-names>C</given-names></name><name><surname>Knau</surname><given-names>A</given-names></name><name><surname>Fichtlscherer</surname><given-names>S</given-names></name><name><surname>Walter</surname><given-names>DH</given-names></name><name><surname>Bruhl</surname><given-names>T</given-names></name><name><surname>Potente</surname><given-names>M</given-names></name><etal/></person-group><article-title>FOXO-dependent expression of the proapoptotic protein Bim: pivotal role for apoptosis signaling in endothelial progenitor cells</article-title><source>FASEB J</source><year>2005</year><volume>19</volume><fpage>974</fpage><lpage>976</lpage><pub-id pub-id-type="pmid">15824087</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ariyasu</surname><given-names>H</given-names></name><name><surname>Takaya</surname><given-names>K</given-names></name><name><surname>Iwakura</surname><given-names>H</given-names></name><name><surname>Hosoda</surname><given-names>H</given-names></name><name><surname>Akamizu</surname><given-names>T</given-names></name><name><surname>Arai</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Transgenic mice overexpressing des-acyl ghrelin show small phenotype</article-title><source>Endocrinology</source><year>2005</year><volume>146</volume><fpage>355</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1210/en.2004-0629</pub-id><pub-id pub-id-type="pmid">15471959</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bahlmann</surname><given-names>FH</given-names></name><name><surname>de Groot</surname><given-names>K</given-names></name><name><surname>Mueller</surname><given-names>O</given-names></name><name><surname>Hertel</surname><given-names>B</given-names></name><name><surname>Haller</surname><given-names>H</given-names></name><name><surname>Fliser</surname><given-names>D</given-names></name></person-group><article-title>Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists</article-title><source>Hypertension</source><year>2005</year><volume>45</volume><fpage>526</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1161/01.HYP.0000159191.98140.89</pub-id><pub-id pub-id-type="pmid">15767470</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thondam</surname><given-names>SK</given-names></name><name><surname>Cross</surname><given-names>A</given-names></name><name><surname>Cuthbertson</surname><given-names>DJ</given-names></name><name><surname>Wilding</surname><given-names>JP</given-names></name><name><surname>Daousi</surname><given-names>C</given-names></name></person-group><article-title>Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with type 2 diabetes mellitus</article-title><source>Diabet med J Br Diabet Assoc</source><year>2012</year><volume>29</volume><fpage>e205</fpage><lpage>e210</lpage><pub-id pub-id-type="doi">10.1111/j.1464-5491.2012.03675.x</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ida</surname><given-names>S</given-names></name><name><surname>Murata</surname><given-names>K</given-names></name><name><surname>Kaneko</surname><given-names>R</given-names></name></person-group><article-title>Effects of metformin treatment on blood leptin and ghrelin levels in patients with type 2 diabetes mellitus</article-title><source>J Diabetes.</source><year>2017</year><volume>9</volume><issue>5</issue><fpage>526</fpage><lpage>535</lpage><pub-id pub-id-type="doi">10.1111/1753-0407.12445</pub-id><pub-id pub-id-type="pmid">27380451</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>CS</given-names></name><name><surname>Lopez</surname><given-names>JA</given-names></name><name><surname>Vuckovic</surname><given-names>S</given-names></name><name><surname>Pyke</surname><given-names>CM</given-names></name><name><surname>Hockey</surname><given-names>RL</given-names></name><name><surname>Hart</surname><given-names>DN</given-names></name></person-group><article-title>Surgical and physical stress increases circulating blood dendritic cell counts independently of monocyte counts</article-title><source>Blood</source><year>2001</year><volume>98</volume><fpage>140</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1182/blood.V98.1.140</pub-id><pub-id pub-id-type="pmid">11418473</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Born</surname><given-names>J</given-names></name><name><surname>Lange</surname><given-names>T</given-names></name><name><surname>Hansen</surname><given-names>K</given-names></name><name><surname>Molle</surname><given-names>M</given-names></name><name><surname>Fehm</surname><given-names>HL</given-names></name></person-group><article-title>Effects of sleep and circadian rhythm on human circulating immune cells</article-title><source>J Immunol</source><year>1997</year><volume>158</volume><fpage>4454</fpage><lpage>4464</lpage><pub-id pub-id-type="pmid">9127011</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>HE</given-names></name><name><surname>Redgrave</surname><given-names>R</given-names></name><name><surname>Cunnington</surname><given-names>MS</given-names></name><name><surname>Avery</surname><given-names>P</given-names></name><name><surname>Keavney</surname><given-names>BD</given-names></name><name><surname>Arthur</surname><given-names>HM</given-names></name></person-group><article-title>Circulating endothelial progenitor cells exhibit diurnal variation</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2008</year><volume>28</volume><fpage>e21</fpage><lpage>e22</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.107.160317</pub-id><pub-id pub-id-type="pmid">18296584</pub-id></element-citation></ref></ref-list></back></article>